McAnear Justin J.'s Form 4 filing
10x Genomics, Inc. (TXG) · filed Oct 5, 2021
- Accession no.
- 0001567619-21-017949
- Filed
- Oct 5, 2021
- Trade date
- Oct 1, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.44M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| McAnear Justin J.CIK 0001786386 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2021 | Class A Common Stock | MOption exerciseAcquired | +10,000 | $5.04 | +$50,400 | 49,100 | Direct | |
| Oct 1, 2021 | Class A Common Stock | SSaleDisposed | −634 | $141.96F2 | −$90,002.64 | 48,466 | Direct | |
| Oct 1, 2021 | Class A Common Stock | SSaleDisposed | −2,500 | $142.80F3 | −$357,000 | 45,966 | Direct | |
| Oct 1, 2021 | Class A Common Stock | SSaleDisposed | −5,666 | $143.79F4 | −$814,714.14 | 40,300 | Direct | |
| Oct 1, 2021 | Class A Common Stock | SSaleDisposed | −1,200 | $144.57F5 | −$173,484 | 39,100 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2021 | Class A Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 380,159 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $141.25 to $142.24. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $142.25 to $143.24. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $143.30 to $144.275. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $144.325 to $145.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.